No Data
Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.
① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.
The pattern of "weak performance of the technology stocks" in the Hong Kong stock market is intensifying. What direction will the market take next?
① Currently, the profit growth of Hong Kong stocks mainly relies on the optimization of profit margins in the Technology Sector rather than revenue expansion. Does this imply that the foundation for sustained market growth in the future is relatively weak? ② For the "Adjustment of Technology Positions + Dividend Hedging" strategy proposed by CICC, how should investors balance the conflict between short-term volatility defense and long-term strategy adherence?
Choosing between A-shares or Hong Kong stocks, Technology or non-Technology? Goldman Sachs' Research Reports respond to two major hot topics in investing in China.
① Currently, should investors continue investing in Hong Kong Stocks or shift to the A-share market? Should the focus be on the Technology Sector or shift to Consumer, Real Estate, and other non-Technology sectors? ② On Wednesday, Goldman Sachs' chief China Stocks strategist, Liu Jinjing, provided an analysis in his report.
Ping An Health Releases 2024 ESG Report
Multiple Institutions have reached a consensus on allocation, decoding the profit code of Ping An Health (1833.HK) "medical insurance synergy."
Recently, Ping An Health released its 2024 Earnings Reports, achieving a revenue of 4.81 billion yuan and an adjusted Net income of 0.158 billion yuan, marking its first annual profit. This report, referred to by the Capital Markets as a "turning point year," quickly attracted intense attention from Brokerages, with institutions such as CITIC SEC, Citigroup, Huachuang Securities, and CSC successively releasing Research Reports. They are Bullish about Ping An Health's future development, clearly giving ratings such as "Buy" and "Recommendation," considering it a high-quality choice for long-term capital strategic allocation. Institutions generally believe that this milestone breakthrough is supported by Ping An Health's efforts in service ecosystem reconstruction, AI technology penetration, payment aspects.
Ping An Health (01833) will achieve comprehensive profitability for the first time in 2024, with multiple Institutions raising their Target Prices.
Recently, Ping An Health (01833) announced its annual performance report for 2024, and its performance in 2024 is outstanding, as the company achieved overall profitability for the first time.
